Table 1: Characteristics of 135 patients with RA evaluated in the current study.

CharacteristicMean ± SD

Age53.63 ± 11.28
Age at onset40.5 ± 12.14

CharacteristicMedian ± IQR

Duration of the disease12 ± 14
Educational level (years) 11 ± 10
Body mass index24.14 ± 5.69
Waist-hip ratio0.92 ± 0.09
Systolic blood pressure120 ± 20
Diastolic blood pressure70 ± 11
C-Reactive protein0.39 ± 1.06
DAS282.75 ± 1.30
HAQ0.99 ± 1.19
TJC physician2 ± 4
SJC physician2 ± 4
TJC patient7 ± 13
SJC patient4 ± 8
SDAI13.72 ± 14.45
CDAI13 ± 13.50

Variablen/N (%)

Sociodemographic

Female106/135 (78.5)
Low educational level59/133 (44.4)
Low socioeconomic status52/132 (39.4)
Ever smoking50/134 (37.3)
Household duties49/135 (36.3)

Clinical aspects

Diabetes5/135 (3.7)
Dyslipidemia28/135 (20.7)
Hypertension56/135 (41.5)
Thrombosis6/135 (4.4)
Osteoporosis42/135 (31.1)
Occlusive arterial disease3/135 (2.2)
Cardiovascular disease63/135 (46.7)
Abnormal body mass index61/133 (45.9)
Abdominal obesity106/134 (79.1)
Physical activity44/135 (32.6)

RA characteristics

Typical morning stiffness100/134 (74.6)
Duration disease > 10 years78/135 (57.9)
Erosions71/108 (65.7)
Nodules40/135 (29.6)
EAMs47/135 (34.8)
EAMs with CVD 87/135 (64.4)
Rheumatoid factor +106/124 (85.5)
Anti CCP +58/70 (89.2)
Methotrexate121/135 (89.6)
DMARD 128/135 (42.2)
Antimalarials106/135 (78.5)
Steroids122/135 (90.4)
Biological agents57/135 (42.2)
Alternative medicine73/130 (56.2)

Autoimmunity

Systemic lupus erythematosus1/135 (0.7)
Autoimmune thyroid disease13/135 (9.6)
Sjögren's syndrome4/135 (3)
Antiphospholipid syndrome2/135 (1.5)
Vitiligo1/135 (0.7)
Scleroderma1/135 (0.7)
Polyautoimmunity19/135 (14.1)
MAS3/135 (2.2)
Familial autoimmunity FDR22/135 (16.3)
Familial autoimmunity SDR5/135 (4.4)
ANAs +63/99 (63.6)

RA: rheumatoid arthritis; SD: standard deviation; IQR: interquartile range; DAS28: disease activity score; HAQ: health assessment questionnaire; TJC: tender joint count; SJC: swollen joint count; SDAI: simplified disease activity index; CDAI: clinical disease activity index; EAMs: extraarticular manifestations; CVD: cardiovascular disease; Anti-CCP: anticyclic citrullinated peptide; DMARD: disease modifying-antirheumatic drugs; MAS: multiple autoimmune syndrome; FDR: first degree relatives; SDR: secondary-degree relatives; ANAs: antinuclear antibodies.